Introduction During a comprehensive presentation by Dr. Catherine Coombs at UC Irvine, insights into the unique challenges and opportunities of…
Browsing: CLL
David J. Andorsky, MD, an Associate Chair for US Oncology Hematology Research and a member of the Rocky Mountain Cancer’s…
By: Christopher Flowers, MD Date: 09/22/2023 Dr. Christopher Flowers of MD Anderson Cancer Center expressed his gratitude to Sandeep for…
Acalabrutinib (AVO): A Promising New Triplet Treatment Option for High-Risk CLL Patients Phase 2 Study Results Matthew Davids By Matthew…
Zanubrutinib compared to ibrutinib in chronic lymphocytic leukemia By Elizabeth Brém, MD from UCI Health We focused basically on two…
Zanubrutinib compared to ibrutinib in chronic lymphocytic leukemia So I’m gonna start with chronic lymphocytic leukemia. And as part of…
Emerging BTK inhibitors are positioned to change the landscape and impact your chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment…
CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL By Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd How…
iFrame is not supported! CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL By Brian Koffman, MDCM (retired), DCFP,…
CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL By Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd How…
Zanubrutinib: Superior PFS in CLL Jennifer Brown, MD – ASH 2022 By Jennifer Brown, MD I’ll be discussing the alpine…
So, I presented the interim analysis of the second part of the FLARE trial, which is a randomized phase 3…